IDH revenue reaches $83 million in first nine months of 2024
Revenue for the period grew from $61.54 million in 2023 to $82.76 million in 2024, a 9 percent increase.
Revenue for the period grew from $61.54 million in 2023 to $82.76 million in 2024, a 9 percent increase.
IDH's core markets of Egypt and Jordan demonstrated strong performance, highlighting resilience despite regional challenges.
El-Sherbini added that IDH’s core markets of Egypt and Jordan displayed strong growth, indicating further potential.
El-Sherbini owns a significant 26.71-percent stake in IDH — this translates to 160,250,305 ordinary shares in the company.
Billionaires.Africa has identified and cataloged various companies and holdings linked to El-Sherbini.
El-Sherbini owns a significant 26.71-percent stake in the company, or 160,250,305 ordinary shares.
El-Sherbini owns a significant 25.5-percent stake in Integrated Diagnostics Holdings.
El-Sherbini owns a significant 25.5-percent stake in Integrated Diagnostics Holdings.
Integrated Diagnostics Holdings is a renowned healthcare services provider.
IDH is a major consumer healthcare group in the Middle East and Africa.
El-Sherbini explained that the ramp-up strategy will create added value for IDH.
El-Sherbini controls a 26.1-percent stake in the group.
El-Sherbini controls a significant 26.1-percent stake in Integrated Diagnostics Holdings.
IDH is one of the Middle East and Africa’s leading consumer healthcare groups.
This is a quarter of the $70-million dividend approved by the board at the end of the 2021 financial year.
IDH is a leading consumer healthcare group in the Middle East and Africa.